Veracyte, Inc. (VCYT)
Pre-Market:
| Previous Close | 33.79 |
| Open | 33.54 |
| Bid | 32.93 x 600 |
| Ask | 33.01 x 300 |
| Day's Range | 32.95 - 34.06 |
| 52 Week Range | 18.61 - 35.51 |
| Volume | |
| Avg. Volume | 932,775 |
| Market Cap | 2.532B |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
Vanguard Group Inc's Strategic Acquisition of Veracyte Inc Shares
Overview of the Recent Transaction On September 30, 2024, Vanguard Group Inc made a significant addition to its investment portfolio by acquiring 251,533 shares of Veracyte Inc (NASDAQ:VCYT), a leader in genomic diagnostics. This transaction increased Vanguard's total holdings in the company to 7,748,514 shares, reflecting a substantial investment in the medical diagnostics sector. The shares were purchased at a price of $34.04 each, marking a strategic move by the firm to bolster its position in the healthcare industry.
- Zacks
3 MedTech Stocks to Buy as Monetary Policy Eases
Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy.
- Zacks
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
